Start your medicinal cannabis journey here
This functionality is only available to residents in Australia.
Our user-friendly service connects everyday Australians with a panel of independent doctors who have experience and knowledge about prescribing medicinal cannabis so they are well qualified to determine patient eligibility.
Helping to guide you on your medicinal cannabis journey.
Street cannabis (including cannabis purchased online) is illegal in Australia. For these products there are no standards or testing requirements adhered to, so the final composition may not be consistent with the label in relation to the amount of THC and CBD. Additionally, these products may also be contaminated with microbes, pesticides and harmful diluents which could cause an adverse event.
The production of prescription medicinal cannabis is subject to the most stringent requirements to protect the health and safety of patients. Producers are required to utilise good production practices in their facility and all products are subject to external testing to ensure it is within TGA accepted tolerance limits and is free from solvents, pesticides, and microbes.
Since the majority of prescription medicinal cannabis is unapproved in Australia, the PBS does not cover the cost for patients. However, 81% of Australian health funds cover medicinal cannabis prescribed via the Special Access Scheme (SAS) or AP programs. Medicinal cannabis is usually covered under Extras (non-PBS pharmacy/pharmaceuticals).¹
What is important to note is that most insurers require the product to be prescribed via the SAS which means that patients using compounded products may not get reimbursed. For more information on PBS and private health cover for legal medicinal cannabis, click here.
In December 2020, the Therapeutic Goods Administration (TGA) announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine). These products must contain at least 98% CBD and 2% or less of other cannabinoids found in cannabis, with a maximum daily dose of 150 mg, and packaged for a 30-day supply for patients over 18 years.
Clinical trials are important for discovering new treatments for conditions such as chronic pain, insomnia, and anxiety. The trials provide valuable information to detect, diagnose, and manage these and other conditions.
Clinical trials can show researchers what does and doesn’t work in humans so helps to grow the knowledge base about medicinal cannabis so that patients can receive the best treatment for their condition including chronic pain, insomnia, and anxiety.
The Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/) is an online registry of clinical trials being undertaken in Australia, and elsewhere. The search function on ANZCTR website enables you to search for medicinal cannabis trials taking place in Australia.
Medicinal cannabis has been legal in Australia since 2016. Australia’s medicines regulator, the Therapeutic Goods Administration (TGA), allows GPs and Specialists to prescribe medicinal cannabis to patients when approved treatments have been ineffective or not tolerated due to side effects.
The TGA provides information for patients about medicinal cannabis products here.
Althea Concierge™ is a free user-friendly online platform supporting patients and healthcare professionals since 2018. As a leading industry support platform, Althea Concierge™ is accessed daily by medical practitioners to provide the best possible care for thousands of Australians, by facilitating the regulatory approval process and providing potential treatment options for conditions that have not gained relief from first line treatments.
Under the care of a GP or Specialist, you can register with Althea Concierge™ to support your medicinal cannabis journey with a pharmacy locator, interactive treatment plan, symptom assessment tool and monitoring plan.